Compare Stocks → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:ADLSOTCMKTS:AVXTOTCMKTS:CORCOTCMKTS:CRXMNASDAQ:GMDA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADLSAdvanced Life Sciences$0.01+9,900.0%$0.01$0.00▼$0.01N/AN/A4,868 shs1,000 shsAVXTAVAX Technologies$0.00$0.00▼$0.00N/AN/A2,410 shsN/ACORCCornwall Resources$0.00$0.00$0.00▼$0.00$2K-26.16N/AN/ACRXMGene Biotherapeutics$0.00$0.00▼$0.00$1KN/AN/AN/AGMDAGamida Cell$0.02$0.21$0.03▼$2.51$2.77M0.939.20 million shs405,165 shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADLSAdvanced Life Sciences0.00%0.00%0.00%0.00%0.00%AVXTAVAX Technologies0.00%0.00%0.00%0.00%0.00%CORCCornwall Resources0.00%0.00%0.00%0.00%-98.00%CRXMGene Biotherapeutics0.00%0.00%0.00%0.00%0.00%GMDAGamida Cell+2.65%-0.64%-95.48%-95.75%-98.99%The Next Step of Their Control Is Here … (Ad)Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADLSAdvanced Life SciencesN/AN/AN/AN/AN/AN/AN/AN/AAVXTAVAX TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACORCCornwall ResourcesN/AN/AN/AN/AN/AN/AN/AN/ACRXMGene BiotherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AGMDAGamida Cell0.6602 of 5 stars3.42.00.00.00.00.80.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADLSAdvanced Life SciencesN/AN/AN/AN/AAVXTAVAX TechnologiesN/AN/AN/AN/ACORCCornwall ResourcesN/AN/AN/AN/ACRXMGene BiotherapeuticsN/AN/AN/AN/AGMDAGamida Cell2.75Moderate Buy$4.7526,288.89% UpsideCurrent Analyst RatingsLatest CRXM, ADLS, AVXT, CORC, and GMDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails1/29/2024GMDAGamida CellJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADLSAdvanced Life SciencesN/AN/AN/AN/AN/AN/AAVXTAVAX TechnologiesN/AN/AN/AN/AN/AN/ACORCCornwall ResourcesN/AN/AN/AN/AN/AN/ACRXMGene BiotherapeuticsN/AN/AN/AN/AN/AN/AGMDAGamida Cell$1.78M1.55N/AN/A($0.02) per share-0.90Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADLSAdvanced Life SciencesN/AN/A0.00∞N/AN/AN/AN/AN/AAVXTAVAX TechnologiesN/AN/A0.00N/AN/AN/AN/AN/AN/ACORCCornwall ResourcesN/AN/A0.00∞N/AN/AN/AN/AN/ACRXMGene BiotherapeuticsN/AN/A0.00N/AN/AN/AN/AN/AN/AGMDAGamida Cell-$63M-$0.63N/A∞N/AN/AN/A-57.59%5/20/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADLSAdvanced Life SciencesN/AN/AN/AN/AN/AAVXTAVAX TechnologiesN/AN/AN/AN/AN/ACORCCornwall ResourcesN/AN/AN/AN/AN/ACRXMGene BiotherapeuticsN/AN/AN/AN/AN/AGMDAGamida CellN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADLSAdvanced Life SciencesN/AN/AN/AAVXTAVAX TechnologiesN/AN/AN/ACORCCornwall ResourcesN/AN/AN/ACRXMGene BiotherapeuticsN/AN/AN/AGMDAGamida Cell213.142.162.09OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADLSAdvanced Life SciencesN/AAVXTAVAX TechnologiesN/ACORCCornwall ResourcesN/ACRXMGene BiotherapeuticsN/AGMDAGamida Cell50.34%Insider OwnershipCompanyInsider OwnershipADLSAdvanced Life Sciences12.00%AVXTAVAX Technologies6.00%CORCCornwall Resources18.40%CRXMGene Biotherapeutics49.80%GMDAGamida Cell3.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADLSAdvanced Life SciencesN/AN/AN/ANot OptionableAVXTAVAX Technologies9N/AN/ANot OptionableCORCCornwall Resources178.44 millionN/ANot OptionableCRXMGene Biotherapeutics314.49 millionN/ANot OptionableGMDAGamida Cell143154.05 million143.70 millionOptionableCRXM, ADLS, AVXT, CORC, and GMDA HeadlinesSourceHeadlineGamida Cell files for U.S. bankruptcy as it undergoes restructuringbizjournals.com - April 23 at 2:12 PMTwo Elbit Medical exit dreams punctured in a weeken.globes.co.il - April 4 at 7:03 PMGamida Cell gets grant for method of preparing transplantable NK cell fraction for transplantationpharmaceutical-technology.com - March 29 at 10:50 AMGoing private last option for Gamida Cell to remain as going concernthepharmaletter.com - March 28 at 2:47 PMGamida Cell to delist as Highbridge takes full ownershipen.globes.co.il - March 28 at 9:46 AMQ4 2023 Gamida Cell Ltd Earnings Callfinance.yahoo.com - March 28 at 1:01 AMGamida Cell, Ltd: Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Managementfinanznachrichten.de - March 27 at 2:52 PMGamida Cell, Ltd: Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Updatefinanznachrichten.de - March 27 at 2:52 PMWhy Gamida Cell Shares Are Falling Todaymsn.com - March 27 at 2:52 PMGMDA Stock Earnings: Gamida Cell Beats EPS, Beats Revenue for Q4 2023investorplace.com - March 27 at 12:05 PMWhy Is Gamida Cell (GMDA) Stock Down 82% Today?investorplace.com - March 27 at 11:16 AMGamida Cell GAAP EPS of $0.57 beats by $0.72, revenue of $1.78M beats by $0.72Mmsn.com - March 27 at 9:51 AMGamida Cell Annual Net Loss Narrows; To Be Taken Privatemarkets.businessinsider.com - March 27 at 9:51 AMGamida Cell starts restructuring process supported by Highbridge Capital, stock downmsn.com - March 27 at 9:51 AMGamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Updateglobenewswire.com - March 27 at 7:00 AMGamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Managementglobenewswire.com - March 27 at 7:00 AMGamida Cell Earnings Previewbenzinga.com - March 27 at 4:51 AMGamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Resultsglobenewswire.com - March 22 at 8:00 AMGamida Cell (GMDA) Earnings Dates & Reportsinvesting.com - March 4 at 8:06 PMGamida Cell (GMDA) Price Target Increased by 8.33% to 4.42msn.com - February 24 at 3:31 PMGamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®globenewswire.com - February 23 at 8:00 AMGamida Cell Stock (NASDAQ:GMDA), Short Interest Reportbenzinga.com - February 22 at 12:03 PMGamida Cell Ltd. (GMDA)finance.yahoo.com - February 21 at 6:00 AMGamida Cell Ltd (GMDA)investing.com - January 30 at 7:30 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAdvanced Life SciencesOTCMKTS:ADLSAdvanced Life Sciences Inc. is a biopharmaceutical company and its lead candidate, Restanza, is a novel once-a-day oral antibiotic in late-stage development for the treatment of life-threatening infections including community-acquired bacterial pneumonia and biodefense pathogens including anthrax, plague and tularemia. The Company has developed a promising pipeline of clinical and preclinical product candidates from both in-licensing efforts and the discovery programs in the areas of infectious disease, oncology, and respiratory disease. It develops ALS-357, a natural product in preclinical studies has demonstrated specific anti-tumor activity against malignant melanoma. It has a unique mechanism of action that disrupts mitochondrial membrane function and is associated with the intrinsic, mitochondria-mediated pathway of apoptosis. The Company develops ALS-886, a novel treatment intended to reduce and prevent the tissue damage associated with diseases such as Adult Respiratory Distress Syndrome (ARDS).AVAX TechnologiesOTCMKTS:AVXTAVAX Technologies, Inc., a development stage biopharmaceutical company, develops autologous cell vaccine technologies for the treatment of cancer. The company's product candidates that have completed phase II clinical trials include M-VAX for the treatment of melanoma and O-VAX for the treatment for ovarian cancer. It also develops LungVax for the treatment of non-small cell lung cancer. The company was formerly known as Walden Laboratories, Inc. and changed its name to AVAX Technologies, Inc. in March 1996. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.Cornwall ResourcesOTCMKTS:CORCCornwall Resources Corp., an independent oil and gas company, acquires and develops oil and gas properties located in Texas and Louisiana Gulf Coast. Cornwall Resources Corp. was formerly known as Columbia Energy Corp. and changed its name to Cornwall Resources Corp. in April 2012. The company was founded in 2006 and is based in Houston, Texas.Gene BiotherapeuticsOTCMKTS:CRXMGene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.Gamida CellNASDAQ:GMDAGamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.